Market revenue in 2023 | USD 94.4 million |
Market revenue in 2030 | USD 128.8 million |
Growth rate | 4.5% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 46.72% in 2023. Horizon Databook has segmented the Middle East & Africa neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
MEA accounted for the lowest market share of 4.4% in 2021. According to global data, the clinical trial activity in the region accounted for 11.2% in 2020. Three countries are leading in terms of clinical trials, primarily Iran followed by South Africa and Egypt.
Conducting clinical trials in MEA has advantages such as patient diversity, cost advantage, infrastructure, and world-class medical facilities. The only drawback is discrepancies between laws of different countries. According to the global data, out of the total trials conducted in the region, only 10.6% of the clinical studies were registered for neurological diseases.
Majority of the trials are focused on infectious diseases and oncology therapy areas due to the high prevalence of cancer and infectious diseases in the region. A continuation of this trend is expected to slow down the market growth in the region to a certain extent.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa neurology clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account